






Lpath, Inc. - Product Pipeline Review - 2015























































  info@wiseguyreports.com  |   
 Chat with us   |    +1 (339) 368 6938 (US)  |     +44 208 133 9349 (UK) 



 Login    Register 






















Home


Report Categories







Premium Reports

Access to 600000+ Premium Reports











  
                                Aerospace & Defense
                              









  
                                Agri & Food
                              









  
                                Automotive
                              









  
                                Basic Materials
                              











  
                                Consumer Goods & Retail
                              









  
                                Energy
                              









  
                                Life Sciences
                              









  
                                Manufacturing & Construction
                              











  
                                Services
                              









  
                                Telecom & IT
                              









  
                                Education
                              









  
                                Security & Intelligence Systems
                              











  
                                Technology
                              









  
                                Company Reports
                              










Report Categories 










Aerospace & Defense
                





Agri & Food
                





Automotive
                





Basic Materials
                







Consumer Goods & Retail
                





Energy
                





Life Sciences
                





Manufacturing & Construction
                







Services
                





Telecom & IT
                





Education
                





Security & Intelligence Systems
                







Technology
                





Company Reports
                








Publisher
Knowledgestore

Countries 
              


Browse by Country
Browse by Continent
Browse by Group / Region



 Conferences
              


Upcoming Conferences
Seminars




 Conferences
              


Upcoming Conferences
Seminars




Countries 

Browse by Country
Browse by Continent
Browse by Group / Region



News & Blog

 Press Release
Blog



News & Blogs

 Press Release
Blogs


FAQs

About Us

About Our Company
Our Team
Life At WGR


Careers
Contact Us











                                         There are no items currently in your basket.
                                     













There are no items currently in your basket!














  




































Search 
                






 














Home
All Reports
Lpath, Inc. - Product Pipeline Review - 2015









 


  Lpath, Inc. - Product Pipeline Review - 2015


WGR70019
29 
                  May, 2015 
Global
34 pages 
Global Markets Direct






















Description




Table of Content




Sample Report




Enquiry before buy




Related Reports





Lpath, Inc. - Product Pipeline Review - 2015SummaryGlobal Markets Direct’s, ‘Lpath, Inc. - Product Pipeline Review - 2015’, provides an overview of the Lpath, Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Lpath, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of Lpath, Inc. including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of Lpath, Inc.’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement - Latest news and deals relating to the Lpath, Inc.’s pipeline productsReasons to buy- Evaluate Lpath, Inc.’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of Lpath, Inc. in its therapy areas of focus- Identify new drug targets and therapeutic classes in the Lpath, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of Lpath, Inc. and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lpath, Inc.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of Lpath, Inc. and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues


Table of ContentsTable of Contents 2List of Tables 3List of Figures 3Lpath, Inc. Snapshot 4Lpath, Inc. Overview 4Key Information 4Key Facts 4Lpath, Inc. - Research and Development Overview 5Key Therapeutic Areas 5Lpath, Inc. - Pipeline Review 7Pipeline Products by Stage of Development 7Pipeline Products - Monotherapy 8Lpath, Inc. - Pipeline Products Glance 9Lpath, Inc. - Clinical Stage Pipeline Products 9Phase II Products/Combination Treatment Modalities 9Phase I Products/Combination Treatment Modalities 10Lpath, Inc. - Early Stage Pipeline Products 11Preclinical Products/Combination Treatment Modalities 11Lpath, Inc. - Drug Profiles 12LT-1009 12Product Description 12Mechanism of Action 12R&D Progress 12Lpathomab 16Product Description 16Mechanism of Action 16R&D Progress 16Altepan 17Product Description 17Mechanism of Action 17R&D Progress 17Lpath, Inc. - Pipeline Analysis 18Lpath, Inc. - Pipeline Products by Target 18Lpath, Inc. - Pipeline Products by Route of Administration 19Lpath, Inc. - Pipeline Products by Molecule Type 20Lpath, Inc. - Pipeline Products by Mechanism of Action 21Lpath, Inc. - Recent Pipeline Updates 22Lpath, Inc. - Dormant Projects 27Lpath, Inc. - Company Statement 28Lpath, Inc. - Locations And Subsidiaries 32Head Office 32Other Locations & Subsidiaries 32Appendix 33Methodology 33Coverage 33Secondary Research 33Primary Research 33Expert Panel Validation 33Contact Us 33Disclaimer 34List of TablesLpath, Inc., Key Information 4Lpath, Inc., Key Facts 4Lpath, Inc. - Pipeline by Indication, 2015 6Lpath, Inc. - Pipeline by Stage of Development, 2015 7Lpath, Inc. - Monotherapy Products in Pipeline, 2015 8Lpath, Inc. - Phase II, 2015 9Lpath, Inc. - Phase I, 2015 10Lpath, Inc. - Preclinical, 2015 11Lpath, Inc. - Pipeline by Target, 2015 18Lpath, Inc. - Pipeline by Route of Administration, 2015 19Lpath, Inc. - Pipeline by Molecule Type, 2015 20Lpath, Inc. - Pipeline Products by Mechanism of Action, 2015 21Lpath, Inc. - Recent Pipeline Updates, 2015 22Lpath, Inc. - Dormant Developmental Projects,2015 27Lpath, Inc., Subsidiaries 32List of FiguresLpath, Inc. - Pipeline by Top 10 Indication, 2015 5Lpath, Inc. - Pipeline by Stage of Development, 2015 7Lpath, Inc. - Monotherapy Products in Pipeline, 2015 8Lpath, Inc. - Pipeline by Top 10 Target, 2015 18Lpath, Inc. - Pipeline by Top 10 Route of Administration, 2015 19Lpath, Inc. - Pipeline by Top 10 Molecule Type, 2015 20Lpath, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 21







                                Request a Sample Report
                                




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Do you have any Specific field of Interest?*

















Confirm


 








Make an enquiry before buying this Report




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Your Enquiry*

















Confirm


 
















Purchase this Market Research Report







 USD




 GBP




 EURO




 YEN




 INR







                        1-user PDF
                         
                          $1,500.00
                        

 
                        Site PDF 
                         
                          $3,000.00
                        

 
                        Enterprise PDF 
                         
                          $4,500.00
                        





  1-user PDF
  
 
    1,154.25
   

 
  Site PDF 
  
 
  2,308.50
  

 
  Enterprise PDF 
  
 
  3,462.75
  





  1-user PDF
  
 
    1,286.40
   

 
  Site PDF 
  
 
  2,572.80
  

 
  Enterprise PDF 
  
 
  3,859.20
  





  1-user PDF
  
 
    166,735.50
   

 
  Site PDF 
  
 
  333,471.00
  

 
  Enterprise PDF 
  
 
  500,206.50
  





  1-user PDF
  
 
    96,690.00
   

 
  Site PDF 
  
 
  193,380.00
  

 
  Enterprise PDF 
  
 
  290,070.00
  









Add To Cart
BUY NOW





 















  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form









  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form






Contact Us










Akash Anand
Domain Head Business Development
sales@wiseguyreports.com
+1 (646) 843 9312 (US)
+44 208 133 9349 (UK)













Rishabh Arora
Domain Head Business Development
sales@wiseguyreports.com
+44-208-133-9346













Abu Koshy
Domain Head Business Development
sales@wiseguyreports.com
+1 339 368 6938










Related Reports








                  ×
              
Tell a friend about this report 




Your Name:*





Your Email:*





Friend's Name:*





Friend's Email:*





Your Enquiry*









Send


 










































Lpath, Inc. - Product Pipeline Review - 2014























































  info@wiseguyreports.com  |   
 Chat with us   |    +1 (339) 368 6938 (US)  |     +44 208 133 9349 (UK) 



 Login    Register 






















Home


Report Categories







Premium Reports

Access to 600000+ Premium Reports











  
                                Aerospace & Defense
                              









  
                                Agri & Food
                              









  
                                Automotive
                              









  
                                Basic Materials
                              











  
                                Consumer Goods & Retail
                              









  
                                Energy
                              









  
                                Life Sciences
                              









  
                                Manufacturing & Construction
                              











  
                                Services
                              









  
                                Telecom & IT
                              









  
                                Education
                              









  
                                Security & Intelligence Systems
                              











  
                                Technology
                              









  
                                Company Reports
                              










Report Categories 










Aerospace & Defense
                





Agri & Food
                





Automotive
                





Basic Materials
                







Consumer Goods & Retail
                





Energy
                





Life Sciences
                





Manufacturing & Construction
                







Services
                





Telecom & IT
                





Education
                





Security & Intelligence Systems
                







Technology
                





Company Reports
                








Publisher
Knowledgestore

Countries 
              


Browse by Country
Browse by Continent
Browse by Group / Region



 Conferences
              


Upcoming Conferences
Seminars




 Conferences
              


Upcoming Conferences
Seminars




Countries 

Browse by Country
Browse by Continent
Browse by Group / Region



News & Blog

 Press Release
Blog



News & Blogs

 Press Release
Blogs


FAQs

About Us

About Our Company
Our Team
Life At WGR


Careers
Contact Us











                                         There are no items currently in your basket.
                                     













There are no items currently in your basket!














  




































Search 
                






 














Home
All Reports
Lpath, Inc. - Product Pipeline Review - 2014









 


  Lpath, Inc. - Product Pipeline Review - 2014


WGR10914
30 
                  May, 2014 
Global
32 pages 
Global Markets Direct






















Description




Table of Content




Sample Report




Enquiry before buy




Related Reports





Lpath, Inc. - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Lpath, Inc. - Product Pipeline Review - 2014’, provides an overview of the Lpath, Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Lpath, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of Lpath, Inc. including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of Lpath, Inc.’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement - Latest news and deals relating to the Lpath, Inc.’s pipeline productsReasons to buy- Evaluate Lpath, Inc.’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of Lpath, Inc. in its therapy areas of focus- Identify new drug targets and therapeutic classes in the Lpath, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of Lpath, Inc. and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lpath, Inc.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of Lpath, Inc. and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues


Table of ContentsTable of Contents 2List of Tables 3List of Figures 3Lpath, Inc. Snapshot 4Lpath, Inc. Overview 4Key Information 4Key Facts 4Lpath, Inc. - Research and Development Overview 5Key Therapeutic Areas 5Lpath, Inc. - Pipeline Review 8Pipeline Products by Stage of Development 8Pipeline Products - Monotherapy 9Lpath, Inc. - Pipeline Products Glance 10Lpath, Inc. - Clinical Stage Pipeline Products 10Phase II Products/Combination Treatment Modalities 10Lpath, Inc. - Early Stage Pipeline Products 11Preclinical Products/Combination Treatment Modalities 11Discovery Products/Combination Treatment Modalities 12Lpath, Inc. - Drug Profiles 13LT-1009 13Product Description 13Mechanism of Action 13R&D Progress 13Lpathomab 17Product Description 17Mechanism of Action 17R&D Progress 17Nextomabs 18Product Description 18Mechanism of Action 18R&D Progress 18Lpath, Inc. - Pipeline Analysis 19Lpath, Inc. - Pipeline Products by Target 19Lpath, Inc. - Pipeline Products by Route of Administration 20Lpath, Inc. - Pipeline Products by Molecule Type 21Lpath, Inc. - Pipeline Products by Mechanism of Action 22Lpath, Inc. - Recent Pipeline Updates 23Lpath, Inc. - Dormant Projects 26Lpath, Inc. - Company Statement 27Lpath, Inc. - Locations And Subsidiaries 30Head Office 30Other Locations & Subsidiaries 30Appendix 31Methodology 31Coverage 31Secondary Research 31Primary Research 31Expert Panel Validation 31Contact Us 32Disclaimer 32List of TablesLpath, Inc., Key Information 4Lpath, Inc., Key Facts 4Lpath, Inc. - Pipeline by Indication, 2014 7Lpath, Inc. - Pipeline by Stage of Development, 2014 8Lpath, Inc. - Monotherapy Products in Pipeline, 2014 9Lpath, Inc. - Phase II, 2014 10Lpath, Inc. - Preclinical, 2014 11Lpath, Inc. - Discovery, 2014 12Lpath, Inc. - Pipeline by Target, 2014 19Lpath, Inc. - Pipeline by Route of Administration, 2014 20Lpath, Inc. - Pipeline by Molecule Type, 2014 21Lpath, Inc. - Pipeline Products by Mechanism of Action, 2014 22Lpath, Inc. - Recent Pipeline Updates, 2014 23Lpath, Inc. - Dormant Developmental Projects,2014 26Lpath, Inc., Subsidiaries 30List of FiguresLpath, Inc. - Pipeline by Top 10 Indication, 2014 6Lpath, Inc. - Pipeline by Stage of Development, 2014 8Lpath, Inc. - Monotherapy Products in Pipeline, 2014 9Lpath, Inc. - Pipeline by Top 10 Target, 2014 19Lpath, Inc. - Pipeline by Top 10 Route of Administration, 2014 20Lpath, Inc. - Pipeline by Top 10 Molecule Type, 2014 21Lpath, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 22







                                Request a Sample Report
                                




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Do you have any Specific field of Interest?*

















Confirm


 








Make an enquiry before buying this Report




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Your Enquiry*

















Confirm


 
















Purchase this Market Research Report







 USD




 GBP




 EURO




 YEN




 INR







                        1-user PDF
                         
                          $1,500.00
                        

 
                        Site PDF 
                         
                          $3,000.00
                        

 
                        Enterprise PDF 
                         
                          $4,500.00
                        





  1-user PDF
  
 
    1,154.25
   

 
  Site PDF 
  
 
  2,308.50
  

 
  Enterprise PDF 
  
 
  3,462.75
  





  1-user PDF
  
 
    1,286.40
   

 
  Site PDF 
  
 
  2,572.80
  

 
  Enterprise PDF 
  
 
  3,859.20
  





  1-user PDF
  
 
    166,735.50
   

 
  Site PDF 
  
 
  333,471.00
  

 
  Enterprise PDF 
  
 
  500,206.50
  





  1-user PDF
  
 
    96,690.00
   

 
  Site PDF 
  
 
  193,380.00
  

 
  Enterprise PDF 
  
 
  290,070.00
  









Add To Cart
BUY NOW





 















  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form









  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form






Contact Us










Akash Anand
Domain Head Business Development
sales@wiseguyreports.com
+1 (646) 843 9312 (US)
+44 208 133 9349 (UK)













Rishabh Arora
Domain Head Business Development
sales@wiseguyreports.com
+44-208-133-9346













Abu Koshy
Domain Head Business Development
sales@wiseguyreports.com
+1 339 368 6938










Related Reports








                  ×
              
Tell a friend about this report 




Your Name:*





Your Email:*





Friend's Name:*





Friend's Email:*





Your Enquiry*









Send


 








































Welcome to Apollo Endosurgery - Apollo Endosurgery, Inc.




























































  


















Changing the way the globalepidemic of obesity is managed.
Changing the way the global epidemic of obesity is managed.

For Patients  
For Professionals











Providing patients with new waysto manage their obesity.
Providing patients with new ways to manage their obesity.

For Patients
For Professionals











Creating a new market forless invasive therapy.

Learn More









ORBERA
LAP-BAND
OverStitch
 




















Changing the way the global epidemic of obesity is managed.
 For PatientsFor Professionals










Providing patients with new ways to manage their obesity.
 For Patients For Professionals










Creating a new market for less invasive therapy.
Learn More








ORBERA
LAP-BAND
OverStitch
 









REVOLUTIONIZING PATIENT CARE
Leading Products in Minimally Invasive Therapies*
 





*
More than 220,000 people have safely used the ORBERA® weight loss balloon.
Learn More





*
A minimally invasive procedure that offers healthy, lasting weight loss.
Learn More





*
Allows physicians to place full-thickness sutures through a flexible endoscope.
Learn More











* Not all products are approved in all markets. Contact your local distributor for a list of Apollo Endosurgery, Inc. products approved for your country.











ORBERA®LAP-BAND®OVERSTITCH™INVESTORSCONTACT USSend InquiryPlace Your OrderCOMPANYAbout UsNewsManagementBoard of DirectorsGlobal LocationsComplianceCareers







Lpath, Inc. - Product Pipeline Review - 2015

























 info@marketreportscenter.com
 +1-646-883-3044 (US) 24x7















LOGIN
SIGN UP














Facebook



Twitter



LinkedIn



Google +



MRC Blog



YouTube







Lpath, Inc. - Product Pipeline Review - 2015

Home >> Pharmaceuticals >> Global Markets Direct >> Lpath, Inc. - Product Pipeline Review - 2015



Report Details





Lpath, Inc. - Product Pipeline Review - 2015







SKU
GMDMAY291571


Category
Pharmaceuticals


Publisher
Global Markets Direct


Pages
34


Published
May-15





SKUGMDMAY291571
CategoryPharmaceuticals
PublisherGlobal Markets Direct
Pages34
Published OnMay-15

Request Discount
Pay by Wire/Invoice





Description
Table of Content
List of Figures
Request Sample




Description
Lpath, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Directs, Lpath, Inc. - Product Pipeline Review - 2015, provides an overview of the Lpath, Inc.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lpath, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Lpath, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Lpath, Inc.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Lpath, Inc.s pipeline products

Reasons to buy

- Evaluate Lpath, Inc.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Lpath, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Lpath, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Lpath, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lpath, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Lpath, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

News/Press Release

Precision Medicine: How the life science industry can improve outcomes through To achieve successful precision medicine at scale and to be able to offer it as an everyday treatment option, researchers in drug R&D need to better understand and manage the reams of unstructured dat...Read More
Regenerative Medicine Market to Hit $53 billion by 2021 The current regenerative medicine market is worth $18.9 billion globally, and will hit over $53 billion by 2021, as impact of Trump administration....Read More
7 Benefits of MicroneedlingMicroneedling: Hundreds of tiny pin pricks going into your skin might sound weird but it could just be the best thing that ever happened to your face....Read More



Table of Content
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Lpath, Inc. Snapshot 4
Lpath, Inc. Overview 4
Key Information 4
Key Facts 4
Lpath, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Lpath, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Lpath, Inc. - Pipeline Products Glance 9
Lpath, Inc. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Lpath, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Lpath, Inc. - Drug Profiles 12
LT-1009 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Lpathomab 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Altepan 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Lpath, Inc. - Pipeline Analysis 18
Lpath, Inc. - Pipeline Products by Target 18
Lpath, Inc. - Pipeline Products by Route of Administration 19
Lpath, Inc. - Pipeline Products by Molecule Type 20
Lpath, Inc. - Pipeline Products by Mechanism of Action 21
Lpath, Inc. - Recent Pipeline Updates 22
Lpath, Inc. - Dormant Projects 27
Lpath, Inc. - Company Statement 28
Lpath, Inc. - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34


List of Figures
List of Tables
Lpath, Inc., Key Information 4
Lpath, Inc., Key Facts 4
Lpath, Inc. - Pipeline by Indication, 2015 6
Lpath, Inc. - Pipeline by Stage of Development, 2015 7
Lpath, Inc. - Monotherapy Products in Pipeline, 2015 8
Lpath, Inc. - Phase II, 2015 9
Lpath, Inc. - Phase I, 2015 10
Lpath, Inc. - Preclinical, 2015 11
Lpath, Inc. - Pipeline by Target, 2015 18
Lpath, Inc. - Pipeline by Route of Administration, 2015 19
Lpath, Inc. - Pipeline by Molecule Type, 2015 20
Lpath, Inc. - Pipeline Products by Mechanism of Action, 2015 21
Lpath, Inc. - Recent Pipeline Updates, 2015 22
Lpath, Inc. - Dormant Developmental Projects,2015 27
Lpath, Inc., Subsidiaries 32
List of Figures
Lpath, Inc. - Pipeline by Top 10 Indication, 2015 5
Lpath, Inc. - Pipeline by Stage of Development, 2015 7
Lpath, Inc. - Monotherapy Products in Pipeline, 2015 8
Lpath, Inc. - Pipeline by Top 10 Target, 2015 18
Lpath, Inc. - Pipeline by Top 10 Route of Administration, 2015 19
Lpath, Inc. - Pipeline by Top 10 Molecule Type, 2015 20
Lpath, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 21







Please Select License Type






Single User Electronic PDF 
$ 1,500.00


Site User Electronic PDF 
$ 3,000.00


Enterprise Wide Electronic PDF 
$ 4,500.00



ADD TO CART

BUY NOW






Related Reports




 Lighting Product Markets in the Top 5 American Countries to 2021 Lighting Product Markets in the Top 5 Asian Countries to 2021 Lighting Product Markets in the Top 5 European Countries to 2021 Global Lighting Product Market to 2021 Lighting Product Markets in Africa to 2021 










Request Sample






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Request Discount






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Pay by Wire/Invoice






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
















Single User Electronic PDF
Site User Electronic PDF
Enterprise Wide Electronic PDF
CD ROM
Hard Copy














SEND










Request Quote






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND









Market Reports Center © Copyright 2017 All rights reserved.









































	Market Report: Lpath, Inc. - Product Pipeline Review - 2015

















































ABOUT US

• PUBLISHERS
• CONTACT US
• CART




Login | Register















All Industries
Business & Finance
-- Business
-- Financial Services
-- Insurance
-- Marketing
Consumer & Food
-- Beverages
-- Consumer Goods
-- Food
-- Retailing
Healthcare
-- Biotechnology
-- Healthcare
-- Medical Devices
-- Pharmaceuticals
Heavy Industry
-- Construction
-- Energy
-- Manufacturing
-- Materials
-- Transportation
Internet & Media
-- E-Business
-- Internet
-- Media
-- Publishing
Public Sector
-- Defense
-- Education
-- Government
Telecom & Computing
-- Computer Technology
-- Fixed Networks
-- Software
-- Wireless
Company/Country Reports
-- Company Reports
-- Country Reports
-- Regional Reports


 
            













                        Processing...




Lpath, Inc. - Product Pipeline Review - 2015

     
                        May 29, 2015 - Global Markets Direct 
                    
                - 34 pages 
                - USD $1,500 
         





Click here to open the POPUP


                        You've added the following report to your cart:CLOSE








Cart Summary



                                    Total Items: 
                                

                                    SubTotal: 
                                


    









Report Summary


Table of Contents


Companies


Request Details


Related







Global Markets Direct's, 'Lpath, Inc. - Product Pipeline Review - 2015', provides an overview of the Lpath, Inc.'s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Lpath, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.ScopeThe report provides brief overview of Lpath, Inc. including business description, key information and facts, and its locations and subsidiariesThe report reviews current pipeline of Lpath, Inc.'s human therapeutic division and enlists all their major and minor projectsThe report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestonesSpecial feature on out-licensed and partnered product portfolioThe report summarizes all the dormant and discontinued pipeline projectsLatest company statementLatest news and deals relating to the Lpath, Inc.'s pipeline productsReasons to buyEvaluate Lpath, Inc.'s strategic position with total access to detailed information on its product pipelineAssess the growth potential of Lpath, Inc. in its therapy areas of focusIdentify new drug targets and therapeutic classes in the Lpath, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areasExploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gapsDevelop strategic initiatives by understanding the focus areas of Lpath, Inc. and exploit collaboration and partnership opportunitiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantagePlan mergers and acquisitions effectively by identifying the most promising pipeline of Lpath, Inc.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeExplore the dormant and discontinued projects of Lpath, Inc. and identify potential opportunities in those areasAvoid Intellectual Property Rights related issues
Table of ContentsList of TablesList of FiguresLpath, Inc. SnapshotLpath, Inc. OverviewKey InformationKey FactsLpath, Inc. - Research and Development OverviewKey Therapeutic AreasLpath, Inc. - Pipeline ReviewPipeline Products by Stage of DevelopmentPipeline Products - MonotherapyLpath, Inc. - Pipeline Products GlanceLpath, Inc. - Clinical Stage Pipeline ProductsPhase II Products/Combination Treatment ModalitiesPhase I Products/Combination Treatment ModalitiesLpath, Inc. - Early Stage Pipeline ProductsPreclinical Products/Combination Treatment ModalitiesLpath, Inc. - Drug ProfilesLT-1009Product DescriptionMechanism of ActionR&D ProgressLpathomabProduct DescriptionMechanism of ActionR&D ProgressAltepanProduct DescriptionMechanism of ActionR&D ProgressLpath, Inc. - Pipeline AnalysisLpath, Inc. - Pipeline Products by TargetLpath, Inc. - Pipeline Products by Route of AdministrationLpath, Inc. - Pipeline Products by Molecule TypeLpath, Inc. - Pipeline Products by Mechanism of ActionLpath, Inc. - Recent Pipeline UpdatesLpath, Inc. - Dormant ProjectsLpath, Inc. - Company StatementLpath, Inc. - Locations And SubsidiariesHead OfficeOther Locations & SubsidiariesAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimerList of TablesLpath, Inc., Key InformationLpath, Inc., Key FactsLpath, Inc. - Pipeline by Indication, 2015Lpath, Inc. - Pipeline by Stage of Development, 2015Lpath, Inc. - Monotherapy Products in Pipeline, 2015Lpath, Inc. - Phase II, 2015Lpath, Inc. - Phase I, 2015Lpath, Inc. - Preclinical, 2015Lpath, Inc. - Pipeline by Target, 2015Lpath, Inc. - Pipeline by Route of Administration, 2015Lpath, Inc. - Pipeline by Molecule Type, 2015Lpath, Inc. - Pipeline Products by Mechanism of Action, 2015Lpath, Inc. - Recent Pipeline Updates, 2015Lpath, Inc. - Dormant Developmental Projects,2015Lpath, Inc., SubsidiariesList of FiguresLpath, Inc. - Pipeline by Top 10 Indication, 2015Lpath, Inc. - Pipeline by Stage of Development, 2015Lpath, Inc. - Monotherapy Products in Pipeline, 2015Lpath, Inc. - Pipeline by Top 10 Target, 2015Lpath, Inc. - Pipeline by Top 10 Route of Administration, 2015Lpath, Inc. - Pipeline by Top 10 Molecule Type, 2015Lpath, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Companies Mentioned in this ReportLpath, Inc.
This report does not have a press release associated with it









Order Today!

FORMAT: PDF 
$1,500  USD
LICENSE: Single User 
DELIVERY: By Email - 1 Business Day


























The Fast Market Research Advantage

Only the Best
            All of our research is sourced from the most trusted and established global analysts and consultancies
Client Focused
            From start-ups to multinationals, we focus on providing the right research to our diverse client base
Shop Securely
            Our US-based customer service team and eCommerce systems adhere to the highest data security standards
Industry-leading Customer Support
            Individualized assistance from our expert staff is never more than an email or phone call away




BEST PRICE GUARANTEE
We are committed to providing the best research at the lowest cost.  We will match any published price for the same report, guaranteed!



EASY ORDERING
Once you’ve found the right report, click ‘order now’ and complete the checkout process
using any major credit card, check or wire/bank transfer.Need multi-user or enterprise license pricing?  Contact us for a custom quote!
                  




About the Publisher
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

Publisher Details







Privacy Policy | Terms of Use | FLASHALERTS


Copyright &copy 2017 Fast Market Research, Inc.



















Lpath, Inc. - Product Pipeline Review - 2015



























Sales and support:
        +44 20 8123 2220 (UK)
        +1 732 587 5005 (US)
info@marketpublishers.com





Business & Finance

Retail






Retail


Consumer Goods


Food & Beverage







Industry

Chemicals

IT & Technology

Life Sciences






Medical Devices
Anesthesia & Respiratory
Cardiovascular Devices
Dental
Diabetes Care
Diagnostic Equipment
Drug Delivery
Endoscopy
Ear, Nose & Throat (ENT)
Healthcare Equipment/Supplies Company Reports
Implants
Neurology
Orthopedic
Ophthalmic
Surgical Equipment
Wound Closure
Other Medical Devices


Biotechnology
Biomarkers
Biomaterials
Biosimilars
Stem Cell

Diagnostics & Diseases
In Vitro Diagnostics
Incontinence
Cancer
Cardiovascular
Diabetes
Hepatitis


Healthcare
Healthcare Services Company Reports
Ear Care
Eye Care
Hospital
Medicated Skin Care
Therapy
Wound Care


Pharmaceuticals
Clinical Trial
Drug Stores
Drugs
Pharmaceuticals Company Reports
Vaccines

Medical Products
Veterinary






Services



About
Faq
 My Cart


 











Market Reports
Press-Releases
Events
About Us
Terms & Conditions
Customer FAQ




Market Research Reports

Life Sciences

Pharmaceuticals





Lpath, Inc. - Product Pipeline Review - 2015





Date:
May 29, 2015



Pages:
34


Price:




US$ 1,500.00




License             [?]:


Single-User License - US$ 1,500.00
Site License - US$ 3,000.00
 Enterprisewide License - US$ 4,500.00




Publisher:
Global Markets Direct


Report type:
Strategic Report


Delivery:

E-mail Delivery (PDF)


ID:
L7E811FD77EEN



        Leaflet:
    

Download PDF Leaflet






















Abstracts
Contents
List of Tables
List of Figures





Lpath, Inc. - Product Pipeline Review - 2015SUMMARYGlobal Markets Direct’s, ‘Lpath, Inc. - Product Pipeline Review - 2015’, provides an overview of the Lpath, Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Lpath, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.SCOPEThe report provides brief overview of Lpath, Inc. including business description, key information and facts, and its locations and subsidiariesThe report reviews current pipeline of Lpath, Inc.’s human therapeutic division and enlists all their major and minor projectsThe report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestonesSpecial feature on out-licensed and partnered product portfolioThe report summarizes all the dormant and discontinued pipeline projectsLatest company statementLatest news and deals relating to the Lpath, Inc.’s pipeline productsREASONS TO BUYEvaluate Lpath, Inc.’s strategic position with total access to detailed information on its product pipelineAssess the growth potential of Lpath, Inc. in its therapy areas of focusIdentify new drug targets and therapeutic classes in the Lpath, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areasExploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gapsDevelop strategic initiatives by understanding the focus areas of Lpath, Inc. and exploit collaboration and partnership opportunitiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantagePlan mergers and acquisitions effectively by identifying the most promising pipeline of Lpath, Inc.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeExplore the dormant and discontinued projects of Lpath, Inc. and identify potential opportunities in those areasAvoid Intellectual Property Rights related issues



    Lpath, Inc. SnapshotLpath, Inc. OverviewKey InformationKey FactsLpath, Inc. - Research and Development OverviewKey Therapeutic AreasLpath, Inc. - Pipeline ReviewPipeline Products by Stage of DevelopmentPipeline Products - MonotherapyLpath, Inc. - Pipeline Products GlanceLpath, Inc. - Clinical Stage Pipeline ProductsPhase II Products/Combination Treatment ModalitiesPhase I Products/Combination Treatment ModalitiesLpath, Inc. - Early Stage Pipeline ProductsPreclinical Products/Combination Treatment ModalitiesLpath, Inc. - Drug ProfilesLT-1009Product DescriptionMechanism of ActionR&D ProgressLpathomabProduct DescriptionMechanism of ActionR&D ProgressAltepanProduct DescriptionMechanism of ActionR&D ProgressLpath, Inc. - Pipeline AnalysisLpath, Inc. - Pipeline Products by TargetLpath, Inc. - Pipeline Products by Route of AdministrationLpath, Inc. - Pipeline Products by Molecule TypeLpath, Inc. - Pipeline Products by Mechanism of ActionLpath, Inc. - Recent Pipeline UpdatesLpath, Inc. - Dormant ProjectsLpath, Inc. - Company StatementLpath, Inc. - Locations And SubsidiariesHead OfficeOther Locations & SubsidiariesAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer


LIST OF TABLESLpath, Inc., Key InformationLpath, Inc., Key FactsLpath, Inc. - Pipeline by Indication, 2015Lpath, Inc. - Pipeline by Stage of Development, 2015Lpath, Inc. - Monotherapy Products in Pipeline, 2015Lpath, Inc. - Phase II, 2015Lpath, Inc. - Phase I, 2015Lpath, Inc. - Preclinical, 2015Lpath, Inc. - Pipeline by Target, 2015Lpath, Inc. - Pipeline by Route of Administration, 2015Lpath, Inc. - Pipeline by Molecule Type, 2015Lpath, Inc. - Pipeline Products by Mechanism of Action, 2015Lpath, Inc. - Recent Pipeline Updates, 2015Lpath, Inc. - Dormant Developmental Projects,2015Lpath, Inc., Subsidiaries


LIST OF FIGURESLpath, Inc. - Pipeline by Top 10 Indication, 2015Lpath, Inc. - Pipeline by Stage of Development, 2015Lpath, Inc. - Monotherapy Products in Pipeline, 2015Lpath, Inc. - Pipeline by Top 10 Target, 2015Lpath, Inc. - Pipeline by Top 10 Route of Administration, 2015Lpath, Inc. - Pipeline by Top 10 Molecule Type, 2015Lpath, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
        
        
Skip to top




MORE PUBLICATIONS


Hospira, Inc. - Product Pipeline Review - 2015
US$ 1,500.00
Aug, 2015 · 39 pages


Advaxis, Inc. - Product Pipeline Review - 2016
US$ 1,500.00
Apr, 2016 · 82 pages


ArQule, Inc. - Product Pipeline Review - 2015
US$ 1,500.00
May, 2015 · 45 pages


Curis, Inc. - Product Pipeline Review - 2015
US$ 1,500.00
May, 2015 · 38 pages








Ask Your Question
Lpath, Inc. - Product Pipeline Review - 2015







Company name*:



Contact person*:



Phone/fax*:



Email*:




 Request invoice


Your enquiry:




				Please click on a Check Box below to confirm you are not a robot:
					


























Market Reports


All Categories  Biotechnology Biomarkers Biomaterials Biosimilars Stem Cell  Diagnostics & Diseases In Vitro Diagnostics Incontinence Cancer Cardiovascular Diabetes Hepatitis  Healthcare Healthcare Services Company Reports Ear Care Eye Care Hospital Medicated Skin Care Therapy Wound Care  Medical Devices Anesthesia & Respiratory Cardiovascular Devices Dental Devices Diabetes Care Diagnostic Equipment Drug Delivery Endoscopy Ear, Nose & Throat (ENT) Devices Healthcare Equipment/Supplies Company Reports Neurology Orthopedic Devices Ophthalmic Surgical Equipment Wound Closure Other Medical Devices  Medical Products Pharmaceuticals Clinical Trials Drug Stores Drugs Pharmaceuticals Company Reports Vaccines  Veterinary 












Sales and support:
                    +44 20 8123 2220
            +1 732 587 5005
info@marketpublishers.com
  © 2006-2016 MarketPublishers.com


About Us
Our Clients
Our Publishers
Customer FAQ


Market Reports
New Publications
Reports by Regions
Press-Releases


Terms & Conditions
Privacy Policy
Return Policy
Affiliate Program


Join as Publisher

Follow Us:






















Lpath, Inc. - Product Pipeline Review - 2015 - RnR Market Research












































Advanced search


1 888 391 5441

sales@rnrmarketresearch.com


Search Market Research Reports






 
 
﻿  Market Research Assistance+ 1-888-391-5441sales@rnrmarketresearch.com

On the Web       

Related Markets
BiotechnologyBiomaterialsBiomarkersStem CellDrug DiscoveryIndustrial BiotechnologyWound CareEnzymeMicroarrayBiopharmaceuticalCell Culture
Related Market ReportsLpath, Inc. - Product Pipeline Review - 2014



Home  
 > Life Sciences > Biotechnology > Report Detail


 

Lpath, Inc. - Product Pipeline Review - 2015


Publisher Name :
Global Markets Direct
 Date: 29-May-2015
No. of pages: 34







Price:

Single User License: US $1500
Corporate User License: US $4500






 
Report DescriptionTable of ContentNews & BlogOther ReportsOur Offerings




Global Markets Direct's, Lpath, Inc. - Product Pipeline Review - 2015', provides an overview of the Lpath, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lpath, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


The report provides brief overview of Lpath, Inc. including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Lpath, Inc.'s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement 
Latest news and deals relating to the Lpath, Inc.'s pipeline products

Reasons to buy

Evaluate Lpath, Inc.'s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of Lpath, Inc. in its therapy areas of focus
Identify new drug targets and therapeutic classes in the Lpath, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of Lpath, Inc. and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lpath, Inc.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Explore the dormant and discontinued projects of Lpath, Inc. and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues


Lpath, Inc. - Product Pipeline Review - 2015
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Lpath, Inc. Snapshot 4
Lpath, Inc. Overview 4
Key Information 4
Key Facts 4
Lpath, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Lpath, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Lpath, Inc. - Pipeline Products Glance 9
Lpath, Inc. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Lpath, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Lpath, Inc. - Drug Profiles 12
LT-1009 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Lpathomab 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Altepan 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Lpath, Inc. - Pipeline Analysis 18
Lpath, Inc. - Pipeline Products by Target 18
Lpath, Inc. - Pipeline Products by Route of Administration 19
Lpath, Inc. - Pipeline Products by Molecule Type 20
Lpath, Inc. - Pipeline Products by Mechanism of Action 21
Lpath, Inc. - Recent Pipeline Updates 22
Lpath, Inc. - Dormant Projects 27
Lpath, Inc. - Company Statement 28
Lpath, Inc. - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables

Lpath, Inc., Key Information 4
Lpath, Inc., Key Facts 4
Lpath, Inc. - Pipeline by Indication, 2015 6
Lpath, Inc. - Pipeline by Stage of Development, 2015 7
Lpath, Inc. - Monotherapy Products in Pipeline, 2015 8
Lpath, Inc. - Phase II, 2015 9
Lpath, Inc. - Phase I, 2015 10
Lpath, Inc. - Preclinical, 2015 11
Lpath, Inc. - Pipeline by Target, 2015 18
Lpath, Inc. - Pipeline by Route of Administration, 2015 19
Lpath, Inc. - Pipeline by Molecule Type, 2015 20
Lpath, Inc. - Pipeline Products by Mechanism of Action, 2015 21
Lpath, Inc. - Recent Pipeline Updates, 2015 22
Lpath, Inc. - Dormant Developmental Projects,2015 27
Lpath, Inc., Subsidiaries 32

List of Figures

Lpath, Inc. - Pipeline by Top 10 Indication, 2015 5
Lpath, Inc. - Pipeline by Stage of Development, 2015 7
Lpath, Inc. - Monotherapy Products in Pipeline, 2015 8
Lpath, Inc. - Pipeline by Top 10 Target, 2015 18
Lpath, Inc. - Pipeline by Top 10 Route of Administration, 2015 19
Lpath, Inc. - Pipeline by Top 10 Molecule Type, 2015 20
Lpath, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 21




High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market  The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …Foremost Trends In Global Pet Care Market The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…China To Review Its Food Security Laws  China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…Improving Standards Of Living To Boost Global Consumer Durables Market  Consumer durables is a cataloguing of consumer goods that are not essential to be bought very often as they are fashioned in a way so as to last for an extended period of time. Profits in the consumer durables sector were most profoundly…

Global Digital PCR Market Research Report 2017

Published:  20-Jul-2017        Price: US 2900 Onwards        Pages: 108 
In this report, the global Digital PCR market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Digital PCR in these regions, from 2012 to 2022 (forecast), covering
- North America
- Europe
- China
- Japan......

Global Cell-based Assays Market Research Report 2017

Published:  20-Jul-2017        Price: US 2900 Onwards        Pages: 129 
In this report, the global Cell-based Assays market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cell-based Assays in these regions, from 2012 to 2022 (forecast), covering
- North America
- Europe
- China
-......

Global DNA Forensic Market Research Report 2017

Published:  20-Jul-2017        Price: US 2900 Onwards        Pages: 115 
In this report, the global DNA Forensic market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of DNA Forensic in these regions, from 2012 to 2022 (forecast), covering
- North America
- Europe
- China
- Japan......

Global Microbial Identification Sales Market Report 2017

Published:  20-Jul-2017        Price: US 4000 Onwards        Pages: 117 
In this report, the global Microbial Identification market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Microbial Identification for these regions, from 2012 to 2022 (forecast), covering
- United States
- China
- Europe......

Global Biopreservation Market 2017-2021

Published:  19-Jul-2017        Price: US 3500 Onwards        Pages: 81 
Bio preservation is a process that uses effective storage techniques to preserve the indigenous functionality and integrity of cells, tissues, and organs at different temperatures for an extended period. Earlier, in the field of tissue engineering, cell and tissue transplantation, and genetic engineering, and preserving of engineered cells and tissues with functional viability in an external environment is a major challenge.
The analysts forecast global bio preservation market to grow......

Competent Cells Market by Type (Chemically, Electrocompetent), Application (Subcloning, Phage Display Library Production, Unstable DNA Cloning, High-Throughput Cloning, Mutagenesis), End User (Pharmaceutical Companies, Academia) - Global Forecast to 2022

Published:  19-Jul-2017        Price: US 5650 Onwards        Pages: 159 
The global competent cells market is projected to reach USD 2.22 billion by 2022 from USD 1.37 billion in 2017, at a CAGR of 10.2%. Advancements in molecular cloning research due to the emergence of new technologies and the growing commercial demand for molecular cloned products and recombinant proteins are some the key factors driving the growth of this market. On the other hand, increasing market consolidation creating strong entry barriers and high cost of competent cells kits are restrain......

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Pipeline Review, H2 2017

Published:  18-Jul-2017        Price: US 3500 Onwards        Pages: 37 
Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Pipeline Review, H2 2017

Summary

Rho Associated Protein Kinase 1 (Renal Carcinoma Antigen NY REN 35 or Rho Associated Coiled Coil Containing Protein Kinase 1 or p160 ROCK 1 or ROCK1 or EC 2.7.11.1) - Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of ......

Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H2 2017

Published:  18-Jul-2017        Price: US 3500 Onwards        Pages: 77 
Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Survival Motor Neuron Protein - Pipeline Review, H2 2017'; Survival Motor Neuron Protein (Component Of Gems 1 or Gemin 1 or SMN1 or SMN2) pipeline Target constitutes close to 17 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. 
......

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2017

Published:  18-Jul-2017        Price: US 3500 Onwards        Pages: 47 
78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2017

Summary

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) pipeline Target constitutes close to 6 molecules. Out of which approximatel......


SERVICES

Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.

Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.

One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.

Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.

Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.

Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.

Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )

Ad Hoc
Pay - as - you - go / Bucket Subscriptions
Fixed Cost for #of reports
Customize / Personalize as per your needs


















 Avail upto 25% Discount on below Publisher Reports.
   
Azoth Analytics 
Technavio













Biotechnology Market Research Reports on Market Size and Competitive Analysis











































Advanced search


1 888 391 5441

sales@rnrmarketresearch.com


Search Market Research Reports






 Market Research Assistance+ 1-888-391-5441sales@rnrmarketresearch.comOn the Web       

Refine ResultBy DateLast MonthLast 3 MonthsLast 6 MonthsLast YearLast 2 Years
By Price< $1000$1000-$2500$2501-$4000$4001-$5500$5501-$7500$7501-$9000>$9000





Home
  >  Life Sciences  >  Biotechnology 




Biotechnology Market Research Reports 

 

Biotechnology, the branch of applied biology that uses biological processes for medicine,engineering, technology, industrial and other purposes. The Biotechnology uses in major areas including, Cloning, Reproductive cloning, therapeutic cloning, environmental biotechnology, genetic engineering, recombinant DNA, tissue engineering and pharmaceutical manufacturing.

The biotechnology market is mainly driven by favorable government initiatives, increasing economic conditions, easily accessibility of funding for R&D, increasing use of biotechnology in medical sciences and agriculture.
The global biotechnology industry is moulded by growth of flexible clinical trial designs, healthcare reform legislation, growing use of healthcare infrastructure, medical device and pharmaceutical taxes and greater  involvement of private companies in biotechnology market.

The market is also registerd growth in mergers and acquisitions followed by patent expiration of various blockbuster drugs and laun...View More
Biotechnology, the branch of applied biology that uses biological processes for medicine,engineering, technology, industrial and other purposes. The Biotechnology uses in major areas including, Cloning, Reproductive cloning, therapeutic cloning, environmental biotechnology, genetic engineering, recombinant DNA, tissue engineering and pharmaceutical manufacturing.

The biotechnology market is mainly driven by favorable government initiatives, increasing economic conditions, easily accessibility of funding for R&D, increasing use of biotechnology in medical sciences and agriculture.
The global biotechnology industry is moulded by growth of flexible clinical trial designs, healthcare reform legislation, growing use of healthcare infrastructure, medical device and pharmaceutical taxes and greater  involvement of private companies in biotechnology market.

The market is also registerd growth in mergers and acquisitions followed by patent expiration of various blockbuster drugs and launching  of newer healthcare regulations. The small companies attempt to 
divest their operation or signed the licensing collaborations and partnerships with the larger companies.

The biotechnology industry is shaped by Human health, followed by agriculture, food, industrial applications and environmental sciences. The investments are made largely in discovery of new drugs and therapies including Cardiology, oncology, diabetes, hormone treatment, antiviral antibody, anemia and inflammation.

The market is led by US, followed by advanced European countries such as UK, France, Spain and Germany and developing countries, particularly India and China. India and China rising as central markets for biotech drugs due to low cost of investment and ample talent pool.

Also, the market is facing several problems such as the smaller companies continue to face problems in raising funds for R&D purposes and poor patent protection for biotech drug makers.View Less


BiochemicalEnzymeBiomaterialsDNA SequencingStem CellCell CultureBiopharmaceuticalDrug DiscoveryWound CareMicroarrayBiomarkersTissue EngineeringRNAi TechnologyProteomicAntibody TechnologyMolecular BiologyGene TherapyAgriculture BiotechnologyGenomicNanomedicineIndustrial BiotechnologyBioinformaticsGenetic EngineeringInformaticAntisense TechnologyEnvironmental Biotechnology

Biotechnology Market Research Reports 

Titlepublishedprice

Asia-Pacific Hemicellulose Market Report 2017By QYResearch Group"......  MT), revenue (Million USD), market share and growth rate of Hemicellulose for these regions, from 2012 to 2022 (forecast), including
- China
- Japan
- South Korea
- Taiwan
- India
- Southeast Asia
- A......"20-Jul-2017$4000

Asia-Pacific Enzymes Market Report 2017By QYResearch Group"...... revenue (Million USD), market share and growth rate of Enzymes for these regions, from 2012 to 2022 (forecast), including
- China
- Japan
- South Korea
- Taiwan
- India
- Southeast Asia
- Australia......"20-Jul-2017$4000

Global Advanced Wound Care Products Sales Market Report 2017By QYResearch Group"......  (K Units), revenue (Million USD), market share and growth rate of Advanced Wound Care Products for these regions, from 2012 to 2022 (forecast), covering
- United States
- China
- Europe
- Japan
- Southeast Asia......"20-Jul-2017$4000

Global Cell-based Assays Market Research Report 2017By QYResearch Group"...... umption, revenue (million USD), market share and growth rate of Cell-based Assays in these regions, from 2012 to 2022 (forecast), covering
- North America
- Europe
- China
- Japan
- Southeast Asia
- India......"20-Jul-2017$2900

Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Dental Gypsum Market 2017 Forecast to 2022By Global Info Research"...... lternatively, to an edentulous arch. The term die is normally used when referring to a replica of a single tooth."Scope of the Report:This report focuses on the Dental Gypsum in Global market, especially in North America, Europ......"20-Jul-2017$4880

Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Cell Culture Market 2017 Forecast to 2022By Global Info Research"...... try of cells and the effects of drugs and toxic compounds on the cells. It is also used in the development of biological compounds.Scope of the Report:This report focuses on the Cell Culture in Global market, especially in Nort......"20-Jul-2017$4880

2017-2022 United States DNA Microarray Market Report (Status and Outlook)By LP Information INC"...... 

In United States market, the top players include
Illumnia
Affymetrix
Agilent
Scienion AG
Applied Microarrays
Arrayit
Sengenics
Biom......"20-Jul-2017$3360

2017-2022 Philippines DNA Microarray Market Report (Status and Outlook)By LP Information INC"...... 
In Philippines market, the top players include
Illumnia
Affymetrix
Agilent
Scienion AG
Applied Microarrays
Arrayit
Sengenics
Biometri......"20-Jul-2017$3360

2017-2022 Malaysia DNA Microarray Market Report (Status and Outlook)By LP Information INC"......  />
In Malaysia market, the top players include
Illumnia
Affymetrix
Agilent
Scienion AG
Applied Microarrays
Arrayit
Sengenics
Biometrix Tech......"20-Jul-2017$3360

2017-2022 Japan DNA Microarray Market Report (Status and Outlook)By LP Information INC"...... 
In Japan market, the top players include
Illumnia
Affymetrix
Agilent
Scienion AG
Applied Microarrays
Arrayit
Sengenics
Biometrix Technology......"20-Jul-2017$3360
 
1 | 2 | 3 | 4 | 5 | 6 | 7 | ...364 | 365next »

 








 Avail upto 25% Discount on below Publisher Reports.
   
Azoth Analytics 
Technavio













Apollo Endosurgery, Inc.                                                                                                 - West Lake Hills                                   , TX         - Company Information









 



























Products
Resources
My Account












Talk to a D&B Advisor 
1-800-280-0780 




Business Directory



TX



West Lake Hills



Electromedical Equipment



Manufacturing - Endoscopic Equipment, Electromedical, Nec



                            Apollo Endosurgery, Inc.
                                    



 





















A 


Apollo Endosurgery, Inc.                                                                                                



1120 S CPITL OF TEXAS HWY WEST LAKE HILLS, TX 78746
Get Directions



(512) 279-5100
 





Business Info



 Founded 2003
 Incorporated NV
 Annual Revenue $64,868,000.00
 Employee Count 3
 Industries Manufacturing - Endoscopic Equipment, Electromedical, Nec
 Contacts Todd Newton                                                                                                             







Contact Business







Your Email Address

Subject:


Message


Send Message





Company Summary


Lpath, Inc., headquartered in San Diego, California, is the category leader in lipid-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are









VERIFIED Status:
UNVERIFIED



Address:
UNVERIFIED





LAST VERIFIED:

                                    --
                                



Phone:

                                    UNVERIFIED
                                





Payment Method:
UNVERIFIED


view full report





Similar Businesses Nearby


                                        Our similar businesses nearby shows similar businesses in their industry and region based on information found in their Dun & Bradstreet Credibility Review profile.                                        







Competitive Landscape


                                        Our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their Dun & Bradstreet Credibility Review profile.                                        







Payments Accepted

NO DATA



Hours



                                        Sunday 

                                        

                                                                                            --
                                            
                                        



                                        Monday 

                                        

                                                                                            --
                                            
                                        



                                        Tuesday 

                                        

                                                                                            --
                                            
                                        



                                        Wednesday 

                                        

                                                                                            --
                                            
                                        



                                        Thursday 

                                        

                                                                                            --
                                            
                                        



                                        Friday 

                                        

                                                                                            --
                                            
                                        



                                        Saturday 

                                        

                                                                                            --
                                            
                                        







A

VIEW ADDITIONAL DATA                        
Select from over 115 networks below to view available data about this business. If this data is unavailable or inaccurate and you own or represent this business, click here for more information on how you may be able to correct it. 







Credibility Review





Google





Facebook.com





Yellowbook.com





Bing.com





Yellowpages.com





MerchantCircle





Tele Atlas (TomTom)





Twitter.com





AOL





MapQuest





Yahoo Local





Apple/Siri





Groupon





Hotfrog.com





Comcast.net Search





ReachLocal





Admedia





Dealsplus





Shoptopia.com





Alteryx





Dogtime Media





KSL.com





Sirtune





AmericanTowns.com





Driverside





Kudzu.com





SpecialsAgent.com





Answers.com





eGood





LawInfo.com





spotlikes.com





anywho.com





eGumball





Likeness.com





Spotzot





eServiceLog





MapMyRun





TechnoCom





apartmentguide.com





ezlocal.com





EZToUse.com





Teleroute





AroundMe.com





metropolist.com





Therapists.com





Atlanta NewHomes





FindLaw.com





Time Out New York





Avantar





FindTheBest.com





mojopages.com





B2B Yellowpages





Fivestar Software





MyCityWay.com





TripAdvisor





bckyrd.com





GiftCards.com





MyCoupons.com





beachcalifornia.com





GoLocal247.com





mymove.com





UpMeSocial.com





Belo





GoodInfo





News-Gazette





Nokia





usdirectory.com





Cars.com





Nomao





Centzy.com





hibu





Openlist.com





ChaCha Search





Homeplate.com





OwnLocal.com





VisiKard





challama.com





Homestore





patch.com





Voltari





CityBot





Pelopidas





Vouchd





ClassifiedAds





Hostway





PlaceIQ





WalkScore.com





CloudMade





Hoodoyou





PlanetDiscover.com





WeddingWire.com





PowerProfiles





Where Inc.





Contractors.com





iGoLocal.com





Radiate Media





Wikiocity





CouponMap





Indeed.com





Wimgo.com





CrowdSpot





Innova Electronics





Intellistrand





realtor.com





DataSphere





InTheMO.com





Reply.com





Yellowbot.com





JiWire





Rocket Fuel





YellowPageCity.com





DMV.org





Justclicklocal.com





Dirxion





Keen.com





Zidster.com












Photos














































Business Credit Report
Receive a one-time comprehensive credit report on this company.
get full credit report


Facebook








Twitter








Yelp






































Call 1.800.280.0780 to speak with a D&B Advisor Today!







Customer Resources
Products
Education Center
Business Articles & Insights
Glossary
Contact Us
Customer Support
Communication Preferences
Search for D&B D-U-N-S




Our Company
About Us
Company History
Business Credit History
Careers
Press Releases
News
Success Stories
Hoovers




Our Network
Partners
Affiliates
Blog
Access to Capital
Entrepreneurial Initiative
D&B International
SupplierEdge




Site Links
Business Directory
Site Map
PIPEDA
Privacy Policy
Website Terms of Service
Product License Agreement







© Dun & Bradstreet, Inc. 2017. All rights reserved.
















Lpath Inc 4025 Sorrento Valley Blvd San Diego, CA Biological Products - MapQuest







































































































    Lpath Inc
  

4025 Sorrento Valley Blvd

San Diego
CA
92121




 Reviews



(858) 678-0800
Website

        Menu & Reservations
      



            Make Reservations 




            Order Online
          

            Tickets
          




          Tickets
        


        See Availability
      





      Nearby
    


      Directions
    


    {{::location.tagLine.value.text}}
  



Sponsored Topics








































See a problem?
Let us know!


  
  
            Founded in 1997, Lpath Incorporated is a biotechnology company that specializes in the discovery and development of lipidomic-based therapeutics that are used to treat human diseases. The company's products include ASONEP, which is a humanized-monoclonal antibody that is used in the treatment of angiogenic-related diseases, inflammatory-oriented disorders, and cancer and multiple sclerosis. It sells iSONEP, which is used for the treatment of age-related macular degeneration, retinopathy and glaucoma. The company also provides drugs for the treatment of fibrotic ocular diseases and fibrosis and neuropathic pain. Lpath Incorporated offers various applications for the detection, treatment and prevention of cardiovascular diseases and disorders. In addition, the company provides compositions and methods for detecting and correlating conditions associated with the altered levels of lysophospholipids.
          






















Legal






Help





















 







Lpath, Inc. - Product Pipeline Review - 2015
















About Us
Solutions 

Resources

eBooks/White Papers
Slideshares
Videos
Blog


Contact Us
Register
Log in
My Account
Logout














Browse Research










My Cart
















Menu  
                                    





 Close   X














Browse








About Us
Solutions
Resources
Contact Us

Log Out
Register
Log in











Life Sciences»Pharmaceuticals»Pharmaceuticals Company Reports 



Lpath, Inc. - Product Pipeline Review - 2015


Lowest Prices Guaranteed
Length
Publisher
Published Date
SKU


from $1,500
34 Pages


Global Markets Direct




May, 2015
                                

GMD5618289





Lowest Prices Guaranteed


Price
from $1,500


Length
34 Pages


Publisher

Global Markets Direct



Published Date

May, 2015

                            


SKU
GMD5618289



Table of Contents




Close Window
Table of Contents




Lpath, Inc. - Product Pipeline Review - 2015


Printer format



Global Markets Direct

Lpath, Inc. Snapshot Lpath, Inc. Overview Key Information Key Facts Lpath, Inc. - Research and Development Overview Key Therapeutic Areas Lpath, Inc. - Pipeline Review Pipeline Products by Stage of Development Pipeline Products - Monotherapy Lpath, Inc. - Pipeline Products Glance Lpath, Inc. - Clinical Stage Pipeline Products Phase II Products/Combination Treatment Modalities Phase I Products/Combination Treatment Modalities Lpath, Inc. - Early Stage Pipeline Products Preclinical Products/Combination Treatment Modalities Lpath, Inc. - Drug Profiles LT-1009 Product Description Mechanism of Action R&D Progress Lpathomab Product Description Mechanism of Action R&D Progress Altepan Product Description Mechanism of Action R&D Progress Lpath, Inc. - Pipeline Analysis Lpath, Inc. - Pipeline Products by Target Lpath, Inc. - Pipeline Products by Route of Administration Lpath, Inc. - Pipeline Products by Molecule Type Lpath, Inc. - Pipeline Products by Mechanism of Action Lpath, Inc. - Recent Pipeline Updates Lpath, Inc. - Dormant Projects Lpath, Inc. - Company Statement Lpath, Inc. - Locations And Subsidiaries Head Office Other Locations & Subsidiaries Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer List of TablesLpath, Inc., Key Information Lpath, Inc., Key Facts Lpath, Inc. - Pipeline by Indication, 2015 Lpath, Inc. - Pipeline by Stage of Development, 2015 Lpath, Inc. - Monotherapy Products in Pipeline, 2015 Lpath, Inc. - Phase II, 2015 Lpath, Inc. - Phase I, 2015 Lpath, Inc. - Preclinical, 2015 Lpath, Inc. - Pipeline by Target, 2015 Lpath, Inc. - Pipeline by Route of Administration, 2015 Lpath, Inc. - Pipeline by Molecule Type, 2015 Lpath, Inc. - Pipeline Products by Mechanism of Action, 2015 Lpath, Inc. - Recent Pipeline Updates, 2015 Lpath, Inc. - Dormant Developmental Projects,2015 Lpath, Inc., Subsidiaries List of FiguresLpath, Inc. - Pipeline by Top 10 Indication, 2015 Lpath, Inc. - Pipeline by Stage of Development, 2015 Lpath, Inc. - Monotherapy Products in Pipeline, 2015 Lpath, Inc. - Pipeline by Top 10 Target, 2015 Lpath, Inc. - Pipeline by Top 10 Route of Administration, 2015 Lpath, Inc. - Pipeline by Top 10 Molecule Type, 2015 Lpath, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 




Description




Close Window
Description




Lpath, Inc. - Product Pipeline Review - 2015


Printer format



Global Markets Direct


Lpath, Inc. - Product Pipeline Review - 2015SummaryGlobal Markets Direct’s, ‘Lpath, Inc. - Product Pipeline Review - 2015’, provides an overview of the Lpath, Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Lpath, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.ScopeThe report provides brief overview of Lpath, Inc. including business description, key information and facts, and its locations and subsidiariesThe report reviews current pipeline of Lpath, Inc.’s human therapeutic division and enlists all their major and minor projectsThe report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones Special feature on out-licensed and partnered product portfolioThe report summarizes all the dormant and discontinued pipeline projectsLatest company statement Latest news and deals relating to the Lpath, Inc.’s pipeline productsReasons to buyEvaluate Lpath, Inc.’s strategic position with total access to detailed information on its product pipelineAssess the growth potential of Lpath, Inc. in its therapy areas of focusIdentify new drug targets and therapeutic classes in the Lpath, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areasExploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gapsDevelop strategic initiatives by understanding the focus areas of Lpath, Inc. and exploit collaboration and partnership opportunitiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantagePlan mergers and acquisitions effectively by identifying the most promising pipeline of Lpath, Inc.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeExplore the dormant and discontinued projects of Lpath, Inc. and identify potential opportunities in those areasAvoid Intellectual Property Rights related issues





Search inside this report




Close Window
Search inside this report
















Online Download
$1,500


Purchase






Site License
$3,000


Purchase






Global Site License
$4,500


Purchase










 



Research assistance



US: 800.298.5699
Int'l: +1.240.747.3093
















      Download our eBook: How to Succeed Using Market Research
    

      Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
    

        Download eBook
    



Share this report









Other tasks

Printer format
Order by fax
Currency converter









































Welcome to Apollo Endosurgery - Apollo Endosurgery, Inc.




























































  


















Changing the way the globalepidemic of obesity is managed.
Changing the way the global epidemic of obesity is managed.

For Patients  
For Professionals











Providing patients with new waysto manage their obesity.
Providing patients with new ways to manage their obesity.

For Patients
For Professionals











Creating a new market forless invasive therapy.

Learn More









ORBERA
LAP-BAND
OverStitch
 




















Changing the way the global epidemic of obesity is managed.
 For PatientsFor Professionals










Providing patients with new ways to manage their obesity.
 For Patients For Professionals










Creating a new market for less invasive therapy.
Learn More








ORBERA
LAP-BAND
OverStitch
 









REVOLUTIONIZING PATIENT CARE
Leading Products in Minimally Invasive Therapies*
 





*
More than 220,000 people have safely used the ORBERA® weight loss balloon.
Learn More





*
A minimally invasive procedure that offers healthy, lasting weight loss.
Learn More





*
Allows physicians to place full-thickness sutures through a flexible endoscope.
Learn More











* Not all products are approved in all markets. Contact your local distributor for a list of Apollo Endosurgery, Inc. products approved for your country.











ORBERA®LAP-BAND®OVERSTITCH™INVESTORSCONTACT USSend InquiryPlace Your OrderCOMPANYAbout UsNewsManagementBoard of DirectorsGlobal LocationsComplianceCareers















Bing Places for Business
























































































































Bing
 places for business


Sign in using your




Microsoft Account





Work Account





Google Account





Facebook Account

Don't have an account? Create one.


